Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update

BACKGROUND: Despite the COVID-19 pandemic, there has been considerable activity in the clinical development of novel and improved drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) during 2020. The agents that were investigated can be divided into “symptomatic” (all...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarthing, Kevin, Rafaloff, Gary, Baptista, Marco A.S., Wyse, Richard K., Stott, Simon R. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Clinical Trials Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461678/
https://www.ncbi.nlm.nih.gov/pubmed/34151864
http://dx.doi.org/10.3233/JPD-219006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461678/
https://www.ncbi.nlm.nih.gov/pubmed/34151864
http://dx.doi.org/10.3233/JPD-219006

Ejemplares similares